Dicerna Pharmaceuticals

DRNA:NAS

Biotechnology

Market Cap

$1.12bn

SMALL cap

Share Price ↑

$16.45 (0.06%)

YTD Return ↑

0.40%

since start of 2019

P/E Ratio

-11.97

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 2007

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.

website

Headquarters

87 Cambridgepark Drive

Cambridge, MA 02140

1.617.621.8097

Executives

Name	Title	Gender
Roberto Guerciolini, MD, MBA	Founder	Male
David Michael Madden, MBA	Chairman	Male
John B. Green, MBA, CPA	Chief Financial Officer	Male
Douglas M. Fambrough, PhD	President, Chief Executive Officer & Director	Male
John J. Rossi, PhD	Founder	Male
Mark A. Behlke, MD, PhD	Founder	Male
James C. Jenson, PhD	Founder	Male
Pankaj Bhargava, MD	Chief Medical Officer	Male
Bob D. Brown, PhD	Chief Scientific Officer & Senior Vice President	Male
David W. Miller, PhD	Senior Vice President-Operations	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A
Pollution Prevention — N/A
Water Conservation — N/A
Data & Privacy Protection — N/A
Consumer Health, Wellness & Safety — N/A
Employee Ownership, Satisfaction, Benefits & Pay — N/A
Workplace Health and Safety — N/A
Integrity of Corporate Governance — N/A
Ethical Practices — N/A
Usage of Conflict Materials — N/A
Forced Labor — N/A
Diversity of Corporate Leadership 1 N/A

Dicerna Pharmaceuticals - Competitors and Related Companies

How Dicerna Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.